Physician profile
Keith William Vrbicky
NPI 1902468937
$346.23
in general payments reported to CMS, 2019-2025
11 companies · $89.35 in 2025
The $89.35 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.83 · 2022: $24.24 · 2023: $65.92 · 2024: $139 · 2025: $89.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.17 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $118.42 | 2024 | Veozah |
| Abbvie INC. | $87.33 | 2021-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $39.44 | 2024-2025 | Zurzuvae |
| Medicem INC. | $19.59 | 2023 | |
| Channel Medsystems, INC. | $18.07 | 2023 | |
| Amag Pharmaceuticals, INC. | $16.59 | 2021 | |
| Dexcom, INC. | $16.40 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $16.02 | 2025 | Mounjaro |
| Exact Sciences Corporation | $14.37 | 2025 | Cologuard Collection Kit |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Vrbicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.